Bedrijfsoverzicht
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical entity dedicated to the development and commercialization of seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension within the United States market, alongside its pipeline candidate GB002, an inhaled small molecule targeting platelet-derived growth factors. Operating within the broader Healthcare sector and the specialized Biotechnology industry, the company functions as a research-driven organization focused on advancing novel therapeutic modalities for serious cardiovascular conditions. The firm currently maintains a market capitalization of $96.11M and employs a workforce of 161 individuals to execute its clinical and operational strategies. With annual revenue recorded at $48.47M, these valuation figures indicate that the company operates as a mid-sized entity in the biotechnology landscape, possessing sufficient capital reserves to fund its clinical development phases while maintaining a relatively lean operational structure compared to large-cap pharmaceutical peers.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $48.47M, yet this generated a net income of -$170,370,000 and an EBITDA of -$163,228,992, revealing a significant gap between top-line sales and bottom-line profitability that highlights a cost structure dominated by high research and development expenditures typical of clinical-stage assets. Free cash flow stands at -$93,332,248, which signifies that the company is burning cash at a rapid pace, thereby limiting its immediate financial flexibility and necessitating ongoing capital raises or the utilization of existing cash reserves to sustain operations. The gross margin is reported at 100.0%, reflecting the nature of early-stage revenue generation or specific accounting treatments for pre-commercial products, whereas the operating margin of -333.6% and profit margin of 0.0% underscore the substantial operational losses incurred relative to revenue generation. On the balance sheet, the company holds $136.93M in cash against total debt obligations of $202.91M, while the debt-to-equity ratio is listed as N/A, indicating a leveraged position where debt exceeds liquid assets. The current ratio of 2.64 suggests that the company possesses 2.64 times more current assets than current liabilities, pointing to adequate short-term liquidity to meet its obligations despite the negative cash flow. Additionally, the return on equity is N/A and the return on assets is -41.9%, metrics that collectively reveal that management is currently deploying capital to generate negative returns as the firm prioritizes asset growth and clinical progress over immediate shareholder value creation.
Waarderingsbeoordeling
The trailing P/E ratio is N/A due to the lack of earnings, while the forward P/E is listed as -2.45, a divergence that implies the market is pricing the stock based on expected future earnings recovery or alternative valuation drivers rather than historical profitability. The price-to-book ratio is -0.78, a negative figure that indicates the market values the company's equity at a discount relative to its book value, a common phenomenon for firms with significant intangible assets or substantial accumulated deficits. Alternative valuation metrics such as the price-to-sales ratio of 1.98 and the EV/EBITDA of -0.99 suggest that investors are willing to pay approximately 1.98 times the company's revenue, prioritizing pipeline potential over current cash flows. The stock has traded between a 52-week low of $0.32 and a 52-week high of $3.87, placing the current valuation within a wide historical range that reflects the high uncertainty and volatility inherent in clinical-stage biotechnology equities. With a beta of 2.16, the stock exhibits price volatility more than twice that of the broader market, indicating that price movements are highly sensitive to sector-specific developments and general market sentiment.
Growth & Income
Revenue growth year-over-year has accelerated to 47.1%, whereas earnings growth is N/A, illustrating that top-line expansion is outpacing any potential earnings improvement as the company navigates its clinical development milestones and incurs increasing costs. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings and cash reserves are being reinvested directly into research, development, and commercialization efforts rather than distributed to shareholders. This strategy aligns with the lifecycle of a clinical-stage biopharmaceutical company, where capital allocation focuses entirely on advancing seralutinib and GB002 through regulatory pathways to achieve commercialization. The overall growth and income profile is characterized by aggressive revenue expansion funded by significant cash burn, with no immediate income generation from dividends but high potential for future value realization upon successful product approval and market entry.